ScreenerHero

CRSP CRISPR Therapeutics AG

NAS · US · Healthcare · Biotechnology · crisprtx.com
52.35USD-3.06%Mkt Cap: 5.06B $P/E: —

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap5.06B USD
Enterprise Value3.64B USD
Revenue (TTM)13.39M USD
Gross Profit-213.48M USD
Net Income (TTM)-581.60M USD
Revenue/Share0.14 USD
Last Price52.35 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.44
PEG—
EV/EBITDA-7.09
EV/Revenue271.86
P/S389.89
P/B2.99
EPS (TTM)-4.46
EPS (Forward)-3.50
52W Range
44.1224% of range78.48
52W High78.48 USD
52W Low44.12 USD
Profitability
Gross Margin0.00%
Oper. Margin-1127.55%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-30.26%
ROA-25.67%
Growth
Revenue Growth1041.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-345.01M USD
CapEx (TTM)25.91M USD
FCF Margin-1611.75%
FCF Yield-4.26%
Net Debt-1.58B USD
Net Debt/EBITDA3.08
Balance Sheet
Debt/Equity0.11
Current Ratio17.85
Quick Ratio17.79
Book Value/Sh18.07 USD
Cash/Share24.45 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)87.56 USD
Upside (mean)+67.3%
Target Range44.00 USD – 291.00 USD
44.00+67.3% to mean291.00
# Analysts18
Ownership
Shares Out.96.69M
Float96.26M
Insiders5.89%
Institutions78.19%
Short Interest
Short Ratio12.8d
Short % Float22.58%
Short % Out.19.72%
Shares Short19.07M
Short (prev mo.)18.74M
Technical
SMA 5054.59 (-4.1%)
SMA 20053.29 (-1.8%)
Beta1.76
S&P 52W Chg16.45%
Avg Vol (30d)1.67M
Avg Vol (10d)1.49M
Technical Indicators
RSI (14)42.8
MACD-0.0141
MACD Signal0.2798
MACD Hist.-0.2939
BB Upper58.97 USD
BB Middle54.83 USD
BB Lower50.68 USD
BB Width15.12%
ATR (14)3.057 USD
Vol Ratio (20d)1.03x